Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GB-0998 for antibody-mediated rejection after renal transplant
jRCT2031200175Completed
- Sponsor
- Japan Blood Products Organization
- Start
- Oct 2020
- Countries
- 1
01
Overview
Open-label, single-arm trial of polyvalent human immunoglobulin in humoral rejection, sponsored by Japan Blood Products Organization. Primary endpoint: Renal graft survival rate at 6 months. Started Oct 2020; status: completed.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
humoral rejection
Beyond the preview
Go deeper on jRCT2031200175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200175.